Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Menveo Market Expected to Grow Between 2025 And 2029?
The market size of Menveo has recently seen an increase of XX (HCAGR). Further projections indicate that it will expand from a valuation of $XX million in 2024 to $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. This positive trend from the past can be traced back to strategies such as public immunization initiatives, the high incidence of meningococcal disease, robust healthcare systems, regulations for international travel, and compulsory vaccinations in the military.
What Growth Rate Is Anticipated for the Menveo Market in the Coming Years?
The market size of Menveo is anticipated to observe XX (FCAGR) growth in the forthcoming years, inflating to a value of $XX million by 2029 at a CAGR of XX%. This projected growth during the forecast tenure is expected to be driven by factors such as a surge in population, increased awareness about healthcare, escalating travel trends, augmenting vaccination requirements in academic institutions, and advancements in emerging markets. The major market trends to dominate the forecast period encompass a surge in combination vaccines, emphasizing booster doses, growing demand from budding economies, improvement in cold-chain distribution, and strategic partnerships for better market infiltration.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20153&type=smp
Who Are the Leading Companies in the Menveo Market?
Major companies operating in the menveo market include GlaxoSmithKline (GSK) Plc
What Are the Key Drivers of the Menveo Market?
The rise in meningitis cases is predicted to drive the growth of the menveo market in the future. Meningitis, an infection that causes inflammation of the protective layers (meninges) surrounding the brain and spinal cord, can be triggered by a range of factors, such as viral, bacterial, or fungal infections. The disease spread is also exacerbated by antibiotic resistance, weakened immunity, and increased global travel. Menveo, a vaccine against meningococcal disease, aids in curbing the meningitis prevalence by shielding against multiple strains of Neisseria meningitides, a primary source of bacterial meningitis. Its extensive use in immunization schedules aids in preventing disease outbreaks and lessening its transfer. For example, the meningococcal reference unit (MRU) of the UK Health Security Agency, a UK government agency, confirmed 396 instances of invasive meningococcal disease (IMD) from 2022 to 2023 in August 2024, showing a significant rise from the 205 cases reported from 2021 to 2022. Consequently, the escalating prevalence of meningitis is fueling the expansion of the menveo market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20153&type=smp
What Are the Key Market Segments in the Menveo Industry?
The menveo market covered in this report is segmented –
1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine
2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination
3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults
4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities
What Are the Latest Trends in the Menveo Market?
One significant trend in the Menveo market is the creation of novel vaccine formulations, such as single-vial, completely liquid versions, for greater ease of use, increased stability, and simplified administration. These single-vial, fully liquid formulations are essentially pre-mixed pharmaceutical products packaged in a single container, with active ingredients already dissolved and prepared for injection. As an example, in November 2024, GlaxoSmithKline (GSK) plc, a pharmaceutical company based in the UK, gained approval from the European Commission (EC) for a fresh version of its meningococcal vaccine, Menveo, intended for active immunization against the invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now licensed for application in children over two years old, adolescents, and adults. Among the notable aspects of the vaccine’s approval include its licensing for active immunization in the European Union targeting children aged two and above, adolescents, and adults, with the new single-vial, fully liquid presentation eliminating the requirement for reconstitution prior to use.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/menveo-global-market-report
What Are the Key Regional Markets in the Menveo Industry?
North America was the largest region in the menveo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20153
This Report Delivers Insight On:
1. How big is the menveo market, and how is it changing globally?
2. Who are the major companies in the menveo market, and how are they performing?
3. What are the key opportunities and risks in the menveo market right now?
4. Which products or customer segments are growing the most in the menveo market?
5. What factors are helping or slowing down the growth of the menveo market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model